Driven by steady growth in its CDMO cell therapy preparation and storage services, Ever Supreme Bio Technology (長聖) saw its 2025 consolidated revenue cross the NT$1 billion threshold for the first time, reaching a record NT$1.027 billion (+9.3% YoY). With the Regenerative Medicine Act officially in effect as of January 1, 2026, the company targets 25% annual growth this year.

Clinical and Regulatory Strategic Outlook:

• Accelerated Pathway: Under the new legislation, Ever Supreme’s CAR001, UMSC01, and Exosome platforms target "life-threatening or severely disabling diseases." Upon completing Phase II with confirmed safety and preliminary efficacy, the company can apply for a 5-year temporary drug license, accelerating commercialization.
• CAR001 (Allogeneic non-viral mRNA CAR.BiTE-γδT): In Phase I/IIa trials for Glioblastoma (GBM), clinical responses showed nearly 80% tumor shrinkage. Notably, it has shown potential in Microsatellite Stable (MSS) solid tumors—typically "cold" tumors unresponsive to standard checkpoint inhibitors. Phase IIa trials are slated for 2026.
• UMSC01: Phase IIa trials are ongoing for Multiple Sclerosis (MS) and Acute Myocardial Infarction (AMI).

Resource: 2025年營收跨過10億大關再創新高 長聖2026年拚年增25％